01.11.2012
- Medical journal The Lancet warned that Sanofi's experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators...
25.10.2012
- Biogen reported much higher-than-expected third-quarter profit on Thursday on increased sales of its drugs for multiple sclerosis and cancer, and the U.S. biotechnology company...
13.08.2012
- Ireland's Elan is to spin off its Neotope drug discovery business platform as a separate public company, making Elan immediately profitable and potentially more appealing as a...
24.07.2012
- Biogen said on Tuesday its second-quarter earnings topped expectations on higher sales of its drugs to treat multiple sclerosis, and the company increased its profit forecast for...
02.05.2012
- Biogen's quarterly profit fell short of analysts' estimates on weak sales of its Avonex multiple sclerosis treatment, its biggest-selling product. But the biotechnology company...
20.04.2012
- European regulators have endorsed the continued use of Novartis's multiple sclerosis pill Gilenya, one of the Swiss firm's top new drug hopes, but said on Friday the drug needed to...
05.07.2010
- Sanofi-Aventis declined to comment on Friday on a Bloomberg report that it was preparing an acquisition of $20 billion or more in the U.S. as shares in the French drugmaker fell...
10.03.2010
- Facet Biotech has agreed to be acquired by Abbott Laboratories for $27 a share, topping a hostile offer of $17.50 a share made last year by Biogen Idec. Shares of Facet rose 67%...
